Castle Biosciences, Inc
Price
FilingsNewest: 10-Q, Quarterly reportJul 30 →InsidersNo open-market buys. 5 insiders sold $10.1M, 107 of 112 sales on a 10b5-1 plan.→HoldersBlackRock 10.8%RTW Investments 9.1%Principal Financial 5.7%→PeersClosest companies: GH, FLGT, PSNL→
From the filings
Figures
- Revenue
- $357.3Mlast 12 months
- Net income
- −$19.4Mlast 12 months
- Operating cash flow
- $48.3Mlast 12 months
- Cash and equivalents
- $62.1Mat the last balance sheet
- Total debt
- $10.1Mat the last balance sheet
- Shares outstanding
- 30.5M shareson issue